Claimable
AI-generated appeals for denied health insurance claims
Our take
Claimable, founded in 2023 by former NHS physician Warris Bokhari, Alicia Graham, and former VA chief data scientist Zach Veigulis, generates custom appeals for denied health insurance claims. Its AI is trained on insurance policies, appeals regulations, legal precedent, and medical literature; a patient answers a short questionnaire, and Claimable drafts the appeal and delivers it to the insurer's appeals department, sometimes copying executives, regulators, and journalists for pressure. It covers 28 conditions and more than 90 treatments, including high-denial categories like GLP-1s, biologics, and autoimmune therapies, at a flat fee of about $50 per case.
The company reports that roughly three quarters or more of its appeals end in reversals, with most cases resolved in about 10 days. It has raised $10M from investors including Mark Cuban and gained national attention through 2025 and 2026 press coverage, including a Bloomberg feature and a TIME100 Health nod for its CEO. For buyers, it sits at the consumer-advocacy end of the denials market: useful for patients and for employers or providers who want a low-lift appeals channel, but not a replacement for enterprise denials management inside a billing office.
What it does
- AI-drafted appeals citing policy terms and medical literature
- Delivery to insurer appeals departments and executives
- Coverage for 28 conditions and 90+ treatments
- Support for 80+ medications including Humira and Dupixent
- Case tracking with most resolved within 10 days
Where it's strong
- Reports roughly 75 to 80% of appeals ending in overturned denials, far above typical patient appeal rates.
- Flat per-case pricing around $50 makes it accessible without a contract or implementation.
- Founding team combines clinical, payer, and VA data science backgrounds, and the escalation tactic of copying executives and regulators gets responses.
What buyers should weigh
- Coverage is limited to a defined list of conditions and treatments, so many denial types are out of scope today.
- The core product is patient-facing; provider and enterprise offerings are newer and less proven at volume.
- It appeals one claim at a time and does not address the upstream documentation or authorization issues driving denials.
Latest
An April 2026 Bloomberg feature reported Claimable has raised $10M from investors including Mark Cuban and has helped reverse thousands of denied claims, and CEO Warris Bokhari was named to the TIME100 Health list.
Also in Denials & Appeals
Adonis
Revenue intelligence and denial prevention
Crosby Health
AI-generated clinical appeals for denied claims
Aspirion
Complex claims and denials recovery for hospitals
Amperos Health
AI biller that works denials by phone and portal
Track this market
First Pass covers Denials & Appeals and the rest of the getting-paid stack every week.